Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | POLA1 | P09884 | 1/20 | 0.74 |
| ▸ | POLD1 | P28340 | 1/20 | 0.74 |
| ▸ | DTYMK | P23919 | 4/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxythymidine_Triphosphate SCHEMBL77832 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Telbivudine 5'Triphosphate SCHEMBL29725270 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL77831 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL887725 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL14279191 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL1579556 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL11055949 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL21275938 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL21682516 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL4370525 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | ILLUMINA, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20210038718-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10821184-B2 | Liquid protein formulations containing thiamine pyrophosphate (TPP) | EAGLE BIOLOGICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9913905-B2 | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | PDE7A, PDE8A, PDE8B | POLB 2213/4885POLA1 2417/4885POLD1 2566/4885 |
| US-10821184-B2 | Liquid protein formulations containing thiamine pyrophosphate (TPP) | PLPBP, ITPA, PLTP | POLB 2992/4885POLA1 3196/4885POLD1 3236/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885POLA1 2702/4885POLD1 2187/4885 |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | NT5C3B, NSUN2, DUT | POLB 42/4885POLA1 229/4885POLD1 269/4885 |
| US-20210038718-A1 | Liquid Protein Formulations Containing Organophosphates | IGFBP1, IGFBP5, IGF2BP1 | POLB 3895/4885POLA1 3458/4885POLD1 3284/4885 |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | IGFBP1, IGFBP5, IGF2BP1 | POLB 3895/4885POLA1 3458/4885POLD1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.